Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Robert Tessarolo, President and Chief Executive Officer, will present at the 2018 Bloom Burton & Co....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. The...

Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratoses (SKs) MISSISSAUGA, ON, April 6, 2018 /CNW/ - Cipher...

Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of...

90% increase in revenue and 214% increase in income from continuing operations for Q4 2017 Canadian launch of OZANEX™ in Jan 2018 Acquired Canadian rights to TRULANCE® in Feb 2018 MISSISSAUGA, ON,

A new differentiated treatment option for GI disorders Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market where innovative treatments are needed...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 and full-year 2017 financial results conference call on Wednesday, February 28, 2018. Q4 AND...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has entered into an exclusive distribution and supply agreement with Italmex Pharma S.A. ("Italmex") under which Cipher has granted Italmex...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo...

Substantially reduces cost of capital and interest expense, provides additional capacity to support future growth MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH)...

Strong Q3 performance 29% revenue growth and 77% growth in income from continuing operations Production resumes at Puerto Rico manufacturing facilities MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher...

In the news release, Notice of Cipher Pharmaceuticals Q2 2017 conference call, issued today at 09:32, please note that an error occurred in the headline which should read "Notice of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on the impact from Hurricane Maria to its manufacturing partner's facilities in Puerto Rico. Galephar...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on a warning letter issued to Cipher by the Office of Prescription Drug Promotion of the U.S. Food and Drug...

Company achieves important strategic milestones, delivers strong financial results MISSISSAUGA, ON, Aug. 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2017 financial results conference call on Friday, August 11, 2017. Q2 2017 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Chris Watters has joined the Company in the new position of Vice President, Corporate Development. Mr....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual Meeting of Shareholders held...

Results highlighted by 92% increase in Adjusted EBITDA, 18% increase in revenue MISSISSAUGA, ON, May 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has completed an agreement (the "Agreement") to sell substantially all of the assets of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2017 financial results conference call and Annual Meeting of shareholders on Thursday, May...

Mark Beaudet expected to be appointed new independent Chair of Board MISSISSAUGA, ON, April 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that it has completed an amendment to the securities purchase agreement (the "Amendment") with investment funds...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2016. Unless otherwise noted,...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it will host a conference call its Q4 and full-year 2016 financial results on Thursday, March 2, 2017. Q4 AND YEAR-END 2016 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR) ("Cipher" or "the Company") today announced that its Board of Directors has approved the voluntary withdrawal of its common shares from NASDAQ...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, Chief Financial Officer and Secretary of the Company, has been named Interim...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in response to a request for comment from Investment Industry Regulatory Organization of Canada ("IIROC") and an...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q3 2016 financial results on Friday, November 11, 2016. Q3 2016 CONFERENCE CALL WHEN:...

Company also announces appointment of Dr. John Mull as Chair of the Board of Directors MISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise...

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board"). As previously disclosed, a special committee of the Board...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016. Q2 2016 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin...

A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

- Revenue increased 23% - Delivered on multiple commercial and regulatory milestones - Positive cash from operating activities of $1.4 million while investing in future growth MISSISSAUGA, ON, May...

Product candidate may have the potential to transform tattoo removal process MISSISSAUGA, ON, May 2, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Beteflam™ (betamethasone valerate), a novel, patent-protected patch,...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S....

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming...

Q4 revenue up 30%, Company significantly advances strategic plans to build a dermatology growth company MISSISSAUGA, ON, Feb. 24, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February...

– Will Represent Fourth Commercial Product in Cipher's Growing Canadian Dermatology Business – MISSISSAUGA, ON, Dec. 7, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, and Norman Evans, Chief Financial...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will be presenting at the TD...

– Quarter Highlighted by 28% Revenue Growth, $2.3 Million in Cash Flow from Operations and Strong Advancement of Pre-Commercial Portfolio – MISSISSAUGA, ON, Nov. 4, 2015 /CNW/ - Cipher...

Cipher Pharmaceutiquired to build its commercial infrastructure in Canada. ____________________ 1 Source: IMS Health. Market share calculated based on total isotretinoin prescriptions. Product...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy"), a Sun Pharma...

– Quarter Highlighted by Continued Solid Performance from Isotretinoin Products and Acquisition and Integration of Innocutis – MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Cipher Pharmaceuticals...

- Acceptance marks first regulatory filing with FDA since Absorica® in 2011 - MISSISSAUGA, ON, Aug. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2015 financial results on Friday, August 14, 2015. Q2 2015 CONFERENCE CALL WHEN:...

- Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 - MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 2015 JMP Securities Life Sciences...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the BIO International Convention in...

- Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio - MISSISSAUGA, ON, June 2, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

– Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa®...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q1 2015 financial results and hold its Annual and Special Meeting of Shareholders on...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor...

Accelerates development of a leading North American dermatology company Adds U.S. commercial infrastructure for our acquisition/in-licensing activities Raises US$100 million Senior Notes to...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will participate at the Laurentian Bank Securities 2nd Annual...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Cowen and Company 35th Annual Health Care...

– Strengthens dermatology product pipeline with rights to three products – MISSISSAUGA, ON, Feb. 26, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2014. Financial...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q4 and year-end 2014 financial results on Wednesday, February 25, 2015. Q4 AND YEAR-END...

Company also announces promotions of Peter Weiler and Linda Angaritis MISSISSAUGA, ON, Jan. 19, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has acquired the assets of Melanovus Oncology Inc. ("Melanovus"), a Hershey (Pennsylvania)-based...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has licensed the Canadian rights to Ozenoxacin, a topical treatment for adult and paediatric...

Cipher Pharmaceuticals Inc. (the "Company") (TSX: CPH; NASDAQ: CPHR) ("Cipher" or "the Company") announced today that its Board of Directors has approved a By-Law (the "Advance Notice By-Law")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare...

Cipher Pharmaceuticals Inc. ("Cipher" or the "Company") (TSX:DND, NASDAQ:CPHR) today announced that its common shares have been approved for listing and trading on the NASDAQ Global Market (the...

- Company also announces application to list on NASDAQ - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 29, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its...

Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q3 2014 financial results on Wednesday, October 29, 2014. Q3 2014 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2014. Q2 2014 Highlights Total revenue of $8.7 million, an...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. ("Ranbaxy") under which Cipher has granted...

Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q2 2014 financial results on Wednesday, July 30, 2014. Q2 2014 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien has been appointed Chief Executive Officer of Cipher, effective June 30. Mr. O'Brien...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco S.A. ("Andrómaco") under which Cipher has...